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use#LAAThe  extreme  response  to  the  paper  by  Nederend  and 
colleagues  [1]  is  that  screening  for  breast  cancer  is 
ineffective. This is, of course, not true. Arguments that 
would deny women access to screening services that have 
advanced  for  more  than  a  decade  [2,3]  have  been 
repeatedly refuted [4-7]. Indeed, more than 40 experts in 
breast health care have severely criticized these methods 
as ‘scientifically unsound’ [8].
The claim that if screening does not reduce the rate of 
advanced cancers, it is ineffective [9,10] is simply false. 
Mammography screening saves lives by finding cancers 
earlier  within  stages  [11].  The  fact  that  Nederend  and 
colleagues did not find a decrease in the rate of advanced 
cancers in their southern Netherlands screening program 
does not mean that there will not be a decrease in deaths.
Since a decrease in advanced cancers has been shown 
to  have  occurred  in  randomized,  controlled  trials  [12] 
and other screening programs [13], including in women 
aged 40 to 49 years [14], this paper raises questions about 
the  screening  program  employed,  not  about  screening 
per se. The reasons for this are multifactorial.
First, they may have overlooked an actual decrease. The 
rate  of  advanced  cancers  reached  almost  180  out  of 
100,000 before screening, and dropped over the screen-
ing period to 160 out of 100,000 for most of the years 
after screening began. In addition, the background rate of 
advanced  cancers  increased  by  almost  50%  over  the 
period among women who were not offered screening. 
Thus, the baseline for comparison was actually increas-
ing,  yielding  screened  women  a  relative  decrease  in 
advanced cancers.
Second,  as  an  economic  measure,  many  European 
screening programs screen only every 2 or more years. 
Periodic screening is not expected to have much effect on 
the  fastest  growing  cancers  (length  bias).  Interrupting 
moderate  and  even  slower  growing  cancers  save  lives. 
The  Swedish  Two-County  trial  shows  that  mortality 
reduction  begins  about  5  to  7  years  after  the  start  of 
screening  with  decreased  deaths  occurring  over  more 
than 20 years [15].
Third, in this Netherlands’ study a large number of the 
advanced cancers were detectable 2 years earlier. With 
annual screening, many of these - as well as some that 
were  not  evident  2  years  earlier  -  might  have  been 
detected a year earlier at a smaller size and earlier stage.
Fourth,  these  results  could  also  be  due  to  the  high 
threshold for intervention used by the radiologists. Many 
of the cancers were evident on the falsely negative screen 
2 years earlier. With a lower threshold, these might have 
been  diagnosed  2  years  earlier  and  have  been  less 
advanced. In the US, where lower thresholds for inter-
vention and higher recall rates have been criticized, there 
was a clear association between the onset of screening in 
the mid-1980s and the decline in breast cancer deaths 
that began in 1990 (for the first time in 50 years) [16], 
fulfilling the criterion by Autier and colleagues [17].
Fifth, the suggestion by some that 30 to 50% of cancers 
found by screening would ‘melt away’ had they not been 
found by mammography is, in my view, based upon faulty 
methodologies [18]. Accurate estimates of ‘overdiagnosis’ 
can  only  come  from  randomized,  controlled  trials  and 
these suggest overdiagnosis rates that are less than 10%, 
and  likely  lower  than  1%  [19].  If  overdiagnosis  is  as 
Abstract
A great deal of misinformation has been promulgated 
about mammography screening. For example, there is 
no biological or scientific support for the use of the age 
of 50 years as a threshold for screening. Mammography 
screening can reduce deaths from breast cancer even 
if the rate of advanced cancers is not decreased. The 
suggestion that screening results in massive amounts 
of overdiagnosis is based upon faulty methodology. 
The results reported in the recent study by Nederend 
and colleagues may be due to the screening interval 
and thresholds used for intervention. What is clear, 
however, is that they do not show that screening is 
ineffective.
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there  not  one  published  series  documenting  breast 
cancers that have ‘melted away’ in the absence of therapy?
Sixth, when cancers are found earlier the mastectomy 
rate is lower, not higher [20], even among women aged 40 
to 49 years [21]. Importantly, the authors failed to adjust 
for lead time, new prevalence cancers being added each 
year, or the increasing baseline incidence of breast cancer. 
The authors should also have looked at the mastectomy 
rates  as  a  function  of  time  period,  since  therapy  has 
changed over time. Many lesions that used to be treated 
by mastectomy in the past are no longer treated in this 
manner.
Despite  its  suggested  failure  to  reduce  advanced 
cancers, the Netherlands screening program will, likely, 
still show a decrease in deaths. Medical oncology groups 
have not joined with recent efforts to reduce the use of 
mammography  screening  for  one  principal  reason: 
because they know that therapies only save lives when 
breast cancers are found earlier.
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